| scholarly article | Q13442814 |
| P50 | author | Murray W Huff | Q87799101 |
| P2093 | author name string | Alexei Kharitonenkov | |
| Christopher L Pin | |||
| Sami A Chadi | |||
| Charis L Johnson | |||
| Elena N Fazio | |||
| Jacqueline Y Weston | |||
| Anja Köester | |||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1795-1804 | |
| P577 | publication date | 2009-08-05 | |
| P1433 | published in | Gastroenterology | Q4039279 |
| P1476 | title | Fibroblast growth factor 21 reduces the severity of cerulein-induced pancreatitis in mice | |
| P478 | volume | 137 |
| Q47244001 | A low-protein diet induces body weight loss and browning of subcutaneous white adipose tissue through enhanced expression of hepatic fibroblast growth factor 21 (FGF21). |
| Q46794318 | A novel function for fibroblast growth factor 21: stimulation of NADPH oxidase-dependent ROS generation |
| Q38459854 | Acinar cell reprogramming: a clinically important target in pancreatic disease |
| Q43491732 | Activating transcription factor 3 promotes loss of the acinar cell phenotype in response to cerulein-induced pancreatitis in mice. |
| Q51362717 | Activating transcription factor 4-dependent induction of FGF21 during amino acid deprivation. |
| Q53438320 | Activation of mTORC1 in skeletal muscle regulates whole-body metabolism through FGF21. |
| Q54526478 | Activation of protein kinase Cδ leads to increased pancreatic acinar cell dedifferentiation in the absence of MIST1. |
| Q33764747 | Association between circulating fibroblast growth factor 21 and mortality in end-stage renal disease |
| Q37298610 | Association of fibroblast growth factor (FGF-21) as a biomarker with primary mitochondrial disorders, but not with secondary mitochondrial disorders (Friedreich Ataxia). |
| Q55193850 | Chemokine CXCL16 mediates acinar cell necrosis in cerulein induced acute pancreatitis in mice. |
| Q34384283 | Data mining reveals a network of early-response genes as a consensus signature of drug-induced in vitro and in vivo toxicity |
| Q51379603 | Direct effects of FGF21 on glucose uptake in human skeletal muscle: implications for type 2 diabetes and obesity. |
| Q36188382 | Elevated Serum Fibroblast Growth Factor 21 in Humans with Acute Pancreatitis |
| Q26781556 | Endocrine FGFs: Evolution, Physiology, Pathophysiology, and Pharmacotherapy |
| Q24629260 | Endocrine fibroblast growth factors 15/19 and 21: from feast to famine |
| Q27335690 | Epigenetic reprogramming in Mist1(-/-) mice predicts the molecular response to cerulein-induced pancreatitis |
| Q50089698 | FGF-21 Elevated IL-10 Production to Correct LPS-Induced Inflammation |
| Q51189900 | FGF21 Is an Exocrine Pancreas Secretagogue. |
| Q64105434 | FGF21 as Modulator of Metabolism in Health and Disease |
| Q27028013 | FGF21 as a Stress Hormone: The Roles of FGF21 in Stress Adaptation and the Treatment of Metabolic Diseases |
| Q35986135 | FGF21 is increased by inflammatory stimuli and protects leptin-deficient ob/ob mice from the toxicity of sepsis |
| Q42034608 | FGF21 mediates the lipid metabolism response to amino acid starvation. |
| Q35755169 | FGF21 regulates PGC-1α and browning of white adipose tissues in adaptive thermogenesis |
| Q38726291 | Fibroblast Growth Factor 21 (FGF21) Promotes Formation of Aerobic Myofibers via the FGF21-SIRT1-AMPK-PGC1α Pathway |
| Q27324101 | Fibroblast Growth Factor 21 (FGF21) Protects against High Fat Diet Induced Inflammation and Islet Hyperplasia in Pancreas |
| Q38794405 | Fibroblast Growth Factor 21 As an Emerging Therapeutic Target for Type 2 Diabetes Mellitus |
| Q36122162 | Fibroblast growth factor 21 (FGF21) inhibits chondrocyte function and growth hormone action directly at the growth plate |
| Q46120307 | Fibroblast growth factor 21 (FGF21) is robustly induced by ethanol and has a protective role in ethanol associated liver injury |
| Q92599809 | Fibroblast growth factor 21 ameliorates pancreatic fibrogenesis via regulating polarization of macrophages |
| Q38058339 | Fibroblast growth factor 21 as an emerging metabolic regulator: clinical perspectives. |
| Q64889156 | Fibroblast growth factor 21 in chronic kidney disease. |
| Q34674492 | Fibroblast growth factor 21 is a metabolic regulator that plays a role in the adaptation to ketosis. |
| Q36061647 | Fibroblast growth factor 21 limits lipotoxicity by promoting hepatic fatty acid activation in mice on methionine and choline-deficient diets |
| Q39017842 | Fibroblast growth factor 21 night watch: advances and uncertainties in the field |
| Q35648897 | Fibroblast growth factor 21 prevents atherosclerosis by suppression of hepatic sterol regulatory element-binding protein-2 and induction of adiponectin in mice. |
| Q46924515 | Fibroblast growth factor 21 protects against acetaminophen-induced hepatotoxicity by potentiating peroxisome proliferator-activated receptor coactivator protein-1α-mediated antioxidant capacity in mice |
| Q87519365 | Fibroblast growth factor 21: a new liver safeguard |
| Q40895648 | Fibroblast growth factor-21 regulates PPARγ activity and the antidiabetic actions of thiazolidinediones. |
| Q35833111 | Forced expression of fibroblast growth factor 21 reverses the sustained impairment of liver regeneration in hPPARα(PAC) mice due to dysregulated bile acid synthesis |
| Q37781747 | Hormone-like (endocrine) Fgfs: their evolutionary history and roles in development, metabolism, and disease |
| Q42857128 | Increased FGF21 plasma levels in humans with sepsis and SIRS. |
| Q35222785 | Increased fibroblast growth factor 21 expression in high-fat diet-sensitive non-human primates (Macaca mulatta). |
| Q26823319 | Inventing new medicines: The FGF21 story |
| Q42322399 | LPS infusion suppresses serum FGF21 levels in healthy adult volunteers |
| Q35835250 | Loss of FGF21 in diabetic mouse during hepatocellular carcinogenetic transformation |
| Q35930185 | MIST1 regulates the pancreatic acinar cell expression of Atp2c2, the gene encoding secretory pathway calcium ATPase 2. |
| Q33685319 | Metabolic role of fibroblast growth factor 21 in liver, adipose and nervous system tissues |
| Q36107291 | Minireview: Roles of Fibroblast Growth Factors 19 and 21 in Metabolic Regulation and Chronic Diseases |
| Q28570349 | Modulating fibroblast growth factor 21 in hyperphagic OLETF rats with daily exercise and caloric restriction |
| Q89666737 | Molecular Mechanism of Pancreatic Stellate Cells Activation in Chronic Pancreatitis and Pancreatic Cancer |
| Q34501606 | Molecular and cellular mechanisms of pancreatic injury |
| Q55490578 | Molecular elements in FGF19 and FGF21 defining KLB/FGFR activity and specificity. |
| Q38241502 | Molecular pathways regulating the formation of brown-like adipocytes in white adipose tissue |
| Q64076256 | Nutritional Regulation of Gene Expression: Carbohydrate-, Fat- and Amino Acid-Dependent Modulation of Transcriptional Activity |
| Q48181118 | Pancreatic gene expression during recovery after pancreatitis reveals unique transcriptome profiles |
| Q51748272 | Photoperiodic regulation of FGF21 production in the Siberian hamster. |
| Q35613153 | Role of fibroblast growth factor 21 in the early stage of NASH induced by methionine- and choline-deficient diet |
| Q89868237 | Serum Fibroblast Growth Factor 21 in Patients with and without Pterygia |
| Q42806569 | Silencing of the Fibroblast growth factor 21 gene is an underlying cause of acinar cell injury in mice lacking MIST1. |
| Q27014973 | Stressed Liver and Muscle Call on Adipocytes with FGF21 |
| Q93180147 | The FGF metabolic axis |
| Q39197925 | The Potential Role of Fibroblast Growth Factor 21 in Lipid Metabolism and Hypertension |
| Q41912342 | The breadth of FGF21's metabolic actions are governed by FGFR1 in adipose tissue |
| Q55513236 | The role of FGF21 in type 1 diabetes and its complications. |
| Q41682512 | Therapeutic potential of GW501516 and the role of Peroxisome proliferator-activated receptor β/δ and B-cell lymphoma 6 in inflammatory signaling in human pancreatic cancer cells |
| Q38633258 | Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23. |
| Q34778879 | Tissue-specific actions of the metabolic hormones FGF15/19 and FGF21. |
| Q36041982 | c-Jun/AP-1 is required for CCK-induced pancreatic acinar cell dedifferentiation and DNA synthesis in vitro. |
Search more.